ライフサイエンスコーパス: decompensated cirrhosis

1 ould be considered in patients admitted with decompensated cirrhosis.

2 patients with genotypes 2 or 3 infection and decompensated cirrhosis.

3 annual number of IDUs developing HCV-related decompensated cirrhosis.

4 g mortality in patients with compensated and decompensated cirrhosis.

5 nt of patients admitted to the hospital with decompensated cirrhosis.

6 and 761 compensated cirrhosis) and 155 with decompensated cirrhosis.

7 njury (AKI) commonly occurs in patients with decompensated cirrhosis.

8 not been well-characterized in patients with decompensated cirrhosis.

9 and potentially inappropriate medications in decompensated cirrhosis.

10 irrhosis but lower sensitivity in those with decompensated cirrhosis.

11 ization across patients with compensated and decompensated cirrhosis.

12 ate prognostic stage between compensated and decompensated cirrhosis.

13 ection, appearing in the setting of advanced decompensated cirrhosis.

14 rdiocirculatory dysfunction in patients with decompensated cirrhosis.

15 orm of kidney injury unique to patients with decompensated cirrhosis.

16 Hospitalization for decompensated cirrhosis.

17 hould be considered a more advanced stage of decompensated cirrhosis.

18 0 (95% CI: 1.17-11.70]) were associated with decompensated cirrhosis.

19 organ dysfunction and death in patients with decompensated cirrhosis.

20 hether the patient has either compensated or decompensated cirrhosis.

21 improve risk stratification in patients with decompensated cirrhosis.

22 combination with rifaximin, in patients with decompensated cirrhosis.

23 in compensated cirrhosis were lower than for decompensated cirrhosis.

24 Similar HRs were observed in patients with decompensated cirrhosis.

25 Simvastatin 40 mg should be avoided in decompensated cirrhosis.

26 1.92 (1.00-3.70) per 100 py in patients with decompensated cirrhosis.

27 osis, and 8.35 (6.05-11.53) in patients with decompensated cirrhosis.

28 ts, driven by a reduction of compensated and decompensated cirrhosis.

29 strategies for PHG and PHPs, particularly in decompensated cirrhosis.

30 tocellular carcinoma and less than half with decompensated cirrhosis.

31 riate medication use in 12,621 patients with decompensated cirrhosis.

32 mong subjects in our cohort of patients with decompensated cirrhosis.

33 n models to explore associating factors with decompensated cirrhosis.

34 ve cases of AKI in patients hospitalized for decompensated cirrhosis.

35 albumin therapy on outcomes of patients with decompensated cirrhosis.

36 igating the role of statins in patients with decompensated cirrhosis.

37 rding the safety of statins in patients with decompensated cirrhosis.

38 t be of therapeutic benefit in patients with decompensated cirrhosis.

39 osis, and finally, (4) patients with CLD and decompensated cirrhosis.

40 ity of improved survival among patients with decompensated cirrhosis.

41 e systemic immune responses in patients with decompensated cirrhosis.

42 ontrol bacterial infections in patients with decompensated cirrhosis.

43 te exacerbation of the SI already present in decompensated cirrhosis.

44 ot been extensively studied in patients with decompensated cirrhosis.

45 should be used with caution in patients with decompensated cirrhosis.

46 response in patients with HCV infection and decompensated cirrhosis.

47 on, including transplantation for those with decompensated cirrhosis.

48 rgery with excellent outcomes for those with decompensated cirrhosis.

49 in the prevalence of cirrhosis (1.7%-2.2%), decompensated cirrhosis (1.1%-1.2%), and HCC (0.03%-0.13

50 in the prevalence of cirrhosis (3.5%-13.2%), decompensated cirrhosis (1.9%-5.8%), and HCC (0.07%-1.6%

51 including compensated cirrhosis (16.3%) and decompensated cirrhosis (10.4%).

52 produced the largest absolute reductions in decompensated cirrhosis (16%) and hepatocellular carcino

53 PMs from ascites samples of 66 patients with decompensated cirrhosis (19 with SBP) and analyzed them

54 is hypothesis and included 522 patients with decompensated cirrhosis (237 with ACLF) and 40 healthy s

55 32% had a diagnosis of cirrhosis (9.9% with decompensated cirrhosis), 36% had a Fibrosis-4 index sco

56 ort screening leads to 84,000 fewer cases of decompensated cirrhosis, 46,000 fewer cases of hepatocel

57 cases of compensated cirrhosis, 3.3 cases of decompensated cirrhosis, 5.5 cases of hepatocellular car

58 Among the full cohort with compensated or decompensated cirrhosis, 61% (504 of 830) died during th

59 f patients with HIV who had cirrhosis (66%), decompensated cirrhosis (62%), and HCC (80%).

60 es of a separate cohort of 111 patients with decompensated cirrhosis (67 with SBP) and quantified the

61 could prevent approximately 124,200 cases of decompensated cirrhosis, 78,800 cases of hepatocellular

62 l in a large cohort of patients with acutely decompensated cirrhosis (AD, n = 52) or acute-on-chronic

63 Independent predictors of mortality were decompensated cirrhosis (adjusted hazard ratio [AHR] 23.

64 Independent predictors of death were decompensated cirrhosis (adjusted hazard ratio [HR] 8.74

65 icipants were randomly allocated following a decompensated cirrhosis admission.

66 Of 6516 patients with cirrhosis, 1152 with decompensated cirrhosis (age 53.2 +/- 11.5 years; 63% me

67 In patients with decompensated cirrhosis, AKI is associated with both hyp

68 In patients hospitalized with decompensated cirrhosis, albumin infusions to increase t

69 was 0.85 (0.75 to 0.97) for compensated and decompensated cirrhosis and 1.05 (0.80 to 1.39) for HCC.

70 cs of systemic inflammation in patients with decompensated cirrhosis and ACLF, with special emphasis

71 pective cohort of hospitalized patients with decompensated cirrhosis and acute kidney injury.

72 Characteristics of decompensated cirrhosis and acute-on-chronic liver failu

73 sis, and medical treatment of a patient with decompensated cirrhosis and AKI suspected to be due to H

74 We aimed to estimate eAlb in patients with decompensated cirrhosis and analyze its relationships wi

75 bundant, activated, and highly functional in decompensated cirrhosis and are further enriched in SBP.

76 Primary HCV infection resulted in decompensated cirrhosis and death within 2-8 years in 4

77 the only effective therapy for patients with decompensated cirrhosis and fulminant liver failure.

78 V, the number of individuals with cirrhosis, decompensated cirrhosis and HCC will continue to increas

79 f patients developing HCV-related cirrhosis, decompensated cirrhosis and HCC will increase substantia

80 nts: a composite of incident compensated and decompensated cirrhosis and HCC.

81 Patients with decompensated cirrhosis and hepatic hydrothorax have hig

82 Decompensated cirrhosis and hepatocellular cancer are ma

83 sis (from 0.86 to 6.32%) and later developed decompensated cirrhosis and hepatocellular carcinoma (HC

84 sis progression, and mortality attributed to decompensated cirrhosis and hepatocellular carcinoma and

85 s of end-stage liver disease (ESLD), such as decompensated cirrhosis and liver cancer.

86 long the survival of rats with irreversible, decompensated cirrhosis and may be useful in the treatme

87 st cost-effective strategy for patients with decompensated cirrhosis and MELD score greater than 13.

88 o-controlled, phase 2 trial in patients with decompensated cirrhosis and moderate-to-severe liver fai

89 ialysis, and liver transplantation [LT]) for decompensated cirrhosis and mortality by race and ethnic

90 Recommendations for management of decompensated cirrhosis and of recurrent hepatitis C aft

91 17 HBsAg-positive patients with decompensated cirrhosis and previous evidence of viral r

92 c function in over half of the patients with decompensated cirrhosis and replicating HBV, and may con

93 e that typically precedes the development of decompensated cirrhosis and the accompanying uncertainti

94 re now presenting in increasing numbers with decompensated cirrhosis and the need for liver transplan

95 controlled trials of adults (>18 years) with decompensated cirrhosis and type 1 hepatorenal syndrome

96 ons of portal hypertension is a harbinger of decompensated cirrhosis and warrants consideration for l

97 Adults aged 18-70 years with newly decompensated cirrhosis and/or HCC were identified using

98 lated mortality; and cumulative incidence of decompensated cirrhosis and/or HCC.

99 Patients with decompensated cirrhosis and/or hepatocellular carcinoma

100 ths, 18,700 (95% UI, 17,600-19,900) cases of decompensated cirrhosis, and 1000 cases of HCC, and 8.9

101 m in 157 patients, including 84 with HCC, 38 decompensated cirrhosis, and 35 acute liver failure.

102 2, advanced fibrosis, compensated cirrhosis, decompensated cirrhosis, and death.

103 ver function in patients with compensated or decompensated cirrhosis, and delay or obviate the need f

104 lculated the annual prevalence of cirrhosis, decompensated cirrhosis, and HCC in a national sample of

105 time trends in the prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (H

106 linical outcomes include cases of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (H

107 ency is common among patients with HCV, with decompensated cirrhosis, and in the posttransplant setti

108 including alcohol-associated hepatitis (AH), decompensated cirrhosis, and metabolic-associated and AL

109 treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and

110 interferon-alpha, the cost of treatment for decompensated cirrhosis, and quality of life in patients

111 patient with hemochromatosis, alcohol abuse, decompensated cirrhosis, and spur cell anemia who had a

112 Patients with decompensated cirrhosis are hospitalized for acute manag

113 Patients with decompensated cirrhosis are not filling indicated medica

114 Patients with decompensated cirrhosis are prescribed numerous medicati

115 Conclusion: One third of patients with decompensated cirrhosis are readmitted within 30 days of

116 nd decreased renal blood flow, patients with decompensated cirrhosis are very susceptible to developi

117 ents with cirrhosis, particularly those with decompensated cirrhosis, are at increased risk of bacter

118 With the rising tide of decompensated cirrhosis associated with metabolic dysfun

119 30, 2018, with clinicians and patients with decompensated cirrhosis at 3 high-volume transplant cent

120 12.7%) died during follow-up, 33 of whom had decompensated cirrhosis at recruitment.

121 18 years or older with any HCV genotype and decompensated cirrhosis at screening.

122 advanced liver disease, including those with decompensated cirrhosis before and after liver transplan

123 advanced liver disease, including those with decompensated cirrhosis before or after liver transplant

124 bservational cohort study of inpatients with decompensated cirrhosis between 2010 and 2013.

125 neurological complications in patients with decompensated cirrhosis, but it is unknown to what exten

126 erial infections are common complications in decompensated cirrhosis, but their relationship with hem

127 tes incubated with plasma from patients with decompensated cirrhosis carrying the protective SNP geno

128 0-200) additional deaths and 2800 additional decompensated cirrhosis cases.

129 equires careful consideration, especially in decompensated cirrhosis cases.

130 ficial effect of lamivudine in patients with decompensated cirrhosis caused by replicating hepatitis

131 ibrosis, compensated cirrhosis Child-Pugh A, decompensated cirrhosis Child-Pugh B or C without (CP B/

132 stance abuse, sexually transmitted diseases, decompensated cirrhosis, cirrhosis, and hepatitis C viru

133 ected with HCV genotypes 1 through 6 who had decompensated cirrhosis (classified as Child-Pugh-Turcot

134 e first patient is a 68-year-old female with decompensated cirrhosis complicated by worsening frailty

135 therapy, recently approved for patients with decompensated cirrhosis (DC) secondary to hepatitis C vi

136 impact of direct-acting antivirals (DAAs) on decompensated cirrhosis (DCC) and HCC in patients with c

137 hronic HCV only, 9% with cirrhosis, 12% with decompensated cirrhosis (DCC), 2% with liver cancer, 2%

138 ients with hepatocellular carcinoma (HCC) or decompensated cirrhosis (DCC).

139 re grouped into HBV-related (subdivided into decompensated cirrhosis [DCC] and hepatocellular carcino

140 as been reported on the real-world clinical (decompensated cirrhosis [DCC] and hepatocellular carcino

141 The incidence of decompensated cirrhosis decreased for UDCA versus OCA or

142 Six patients have died; 1 patient with decompensated cirrhosis died of variceal bleeding.

143 Circulating albumin in patients with decompensated cirrhosis displayed multiple structural ab

144 The prevalence of patients with decompensated cirrhosis doubled, from 5% in 1996 to 11%

145 rcaserin in a morbidly obese individual with decompensated cirrhosis evaluated for LT listing.

146 Most patients with decompensated cirrhosis fail to meet their nutrition tar

147 phageal variceal hemorrhage in patients with decompensated cirrhosis (first section); we reviewed the

148 rall LREA events and may not be effective in decompensated cirrhosis for this end point.

149 ecrease the 15-year cumulative incidences of decompensated cirrhosis from 12.2% to 4.5%, hepatocellul

150 enrolled HCV treatment-naive persons without decompensated cirrhosis from 5 countries.

151 ificantly larger proportion of patients with decompensated cirrhosis given a combination of G-CSF and

152 nt-reported outcomes (PROs) in patients with decompensated cirrhosis given a fixed-dose combination o

153 oup 1), compensated cirrhosis (group 2), and decompensated cirrhosis (group 3).

154 , despite a guarded prognosis, patients with decompensated cirrhosis had inadequate ACP throughout th

155 Acute kidney injury in decompensated cirrhosis has limited therapeutic options,

156 Patients with decompensated cirrhosis have significantly reduced survi

157 ing, we predict the incidence of CHC-induced decompensated cirrhosis, HCC, and liver-related deaths w

158 es were defined by fibrosis states F0 to F4, decompensated cirrhosis, hepatocellular carcinoma (HCC),

159 esponse, chronic HCV, compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver

160 f HCV incidence, prevalence, compensated and decompensated cirrhosis, hepatocellular carcinoma, liver

161 H-fibrosis, NASH-compensated cirrhosis, NASH-decompensated cirrhosis, hepatocellular carcinoma, liver

162 ho experienced a liver disease complication (decompensated cirrhosis, hepatocellular carcinoma, or li

163 ge IV disease (HR, 1.40; 95% CI, 1.24-1.58), decompensated cirrhosis (HR, 1.49; 95% CI, 1.30-1.70), a

164 ed cirrhosis [risk ratio: 1.74 (1.24, 2.45)] decompensated cirrhosis [HR: 3.82 (1.60, 9.10)], HCC [HR

165 phase 3 trial conducted among patients with decompensated cirrhosis in 14 European hospitals between

166 SVR-12 in hepatitis C virus-related decompensated cirrhosis in a predominant genotype 3 popu

167 g a second-line therapy as a risk factor for decompensated cirrhosis in a real-world population with

168 The number of IDUs developing HCV-related decompensated cirrhosis in Scotland is estimated to doub

169 cellular carcinoma, and 203,000 will develop decompensated cirrhosis in the next 35 years.

170 PBC, and identify the predictive factors for decompensated cirrhosis in these patients.

171 Management of obesity and decompensated cirrhosis in those requiring liver transpl

172 advanced liver disease, including those with decompensated cirrhosis, in routine practice (all curren

173 hort of Latin American patients with acutely decompensated cirrhosis, increasing percentages of Nativ

174 , for patients admitted to the hospital with decompensated cirrhosis, individuals who were managed by

175 Improving the care of decompensated cirrhosis is a significant clinical challe

176 Decompensated cirrhosis is associated with high morbidit

177 Chronic hepatitis C-related decompensated cirrhosis is associated with lower sustain

178 Decompensated cirrhosis is characterized by disturbed sy

179 irus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase.

180 The prognosis of patients with decompensated cirrhosis is poor, with significantly incr

181 including patients with HIV/HCV coinfection, decompensated cirrhosis, liver and kidney transplants, a

182 es F1 to F3 with or without MASH, cirrhosis, decompensated cirrhosis, liver cancer, liver transplant,

183 In patients with decompensated cirrhosis, liver transplant should be cons

184 Decompensated cirrhosis, low body mass index and older a

185 ging from early, ambulatory-phase disease to decompensated cirrhosis necessitating liver transplantat

186 were studied in patients with hypotension or decompensated cirrhosis of the liver.

187 sease distinguishes acute liver failure from decompensated cirrhosis or acute-on-chronic liver failur

188 e risk of infection in patients with acutely decompensated cirrhosis or ESLD.

189 ical treatments that can halt progression to decompensated cirrhosis or even reverse cirrhosis are cu

190 9, treatment-naive patients with HCV without decompensated cirrhosis or liver cancer were recruited t

191 ction of any genotype and either compensated/decompensated cirrhosis or posttransplantation recurrenc

192 al need is great, treatment of patients with decompensated cirrhosis or with recurrent hepatitis C af

193 eatening liver disease (acute liver failure, decompensated cirrhosis, or severe hepatitis flare) and

194 nsideration are patients with compensated or decompensated cirrhosis, organ transplantation, acute he

195 utive patients admitted to the hospital with decompensated cirrhosis over a 1-year period were identi

196 underwent liver transplantation at UCLA for decompensated cirrhosis owing to a jejunoileal bypass we

197 term administration can modify the course of decompensated cirrhosis patients by reducing the onset o

198 that the optimal MELD threshold below which decompensated cirrhosis patients should receive HCV trea

199 re to predict 30-day hospital readmission in decompensated cirrhosis patients using the US nationwide

200 More specifically, in decompensated-cirrhosis patients, "high-risk" grafts did

201 One patient who had decompensated cirrhosis prior to treatment initiation di

202 Patients with decompensated cirrhosis receiving DAAs present lower res

203 Three patients are described who developed decompensated cirrhosis requiring retransplantation desp

204 CI], 2.62-4.49; P < .001, log-rank test) and decompensated cirrhosis (RR = 4.11; 95% CI, 2.95-5.70; P

205 [CI]=1.11-2.11; log-rank test; P<0.001) and decompensated cirrhosis (RR=2.01; 95% CI=1.07-3.79; log-

206 prospective study, consecutive patients with decompensated cirrhosis seen at the Institute of Liver a

207 In patients with advanced and decompensated cirrhosis, serum albumin levels are low be

208 and clinical characteristics, patients with decompensated cirrhosis spent 15.2 days (95% CI: 14.4 to

209 ed with systemic inflammation differentiated decompensated cirrhosis states from compensated cirrhosi

210 of the pathophysiological cascade underlying decompensated cirrhosis, such as systemic inflammatory s

211 study provides the evidence in patients with decompensated cirrhosis that eAlb can be quantified and

212 er transplantation (LT) offers patients with decompensated cirrhosis the best chance at long-term sur

213 mpensated cirrhosis) to a symptomatic phase (decompensated cirrhosis), the complications of which oft

214 However, in decompensated cirrhosis, the impact of etiologic treatme

215 0.61; 95% CI, 0.47-0.79) among patients with decompensated cirrhosis, the median survival benefit was

216 ional study of individuals hospitalized with decompensated cirrhosis, there were racial and ethnic di

217 ended in specific patient groups: those with decompensated cirrhosis, those coinfected with human imm

218 This validated model enabled patients with decompensated cirrhosis to be stratified into groups wit

219 nd improved quality of life in patients with decompensated cirrhosis treated with continuous terlipre

220 The monthly cost of care for decompensated cirrhosis was $3969.30, which was 59.3% ($

221 The 15 year cumulative incidence of decompensated cirrhosis was 15.6% (95% CI, 0-31.3%) in t

222 alence of alcohol-associated compensated and decompensated cirrhosis was 23.6 million and 2.5 million

223 e probability of survival after diagnosis of decompensated cirrhosis was 81.8 and 50.8% at 1 and 5 ye

224 in 40 mg/day plus rifaximin in patients with decompensated cirrhosis was associated with a significan

225 Decompensated cirrhosis was associated with male sex (ad

226 Decompensated cirrhosis was defined as current or past e

227 he prominence of vascular destabilization in decompensated cirrhosis, we evaluated Angiopoietin-2 to

228 hemodynamic derangements than patients with decompensated cirrhosis, we investigated whether PICD co

229 ndividuals with additional liver diseases or decompensated cirrhosis were excluded.

230 267 patients with HCV-related decompensated cirrhosis were included.

231 ASTRAL-4) in which patients with HCV-related decompensated cirrhosis were randomly assigned to an all

232 Eighty patients with decompensated cirrhosis were recruited (40 each with and

233 eir high risk of hypoglycemia, especially in decompensated cirrhosis where insulin is the only therap

234 th fibrosing cholestatic hepatitis (FCH) and decompensated cirrhosis who had a life expectancy of 1 y

235 p trial involving hospitalized patients with decompensated cirrhosis who had a serum albumin level of

236 Adult patients with confirmed diagnosis of decompensated cirrhosis who were admitted to the ICU bet

237 Os was observed in patients with HCV-related decompensated cirrhosis who were given sofosbuvir and ve

238 everal others, in 1274 patients with acutely decompensated cirrhosis who were nonelectively admitted

239 ve was to identify LT-eligible patients with decompensated cirrhosis who would benefit (and not benef

240 ) correlates with mortality in patients with decompensated cirrhosis, who are almost invariably sarco

241 ere is a concern that the cured patient with decompensated cirrhosis will find themselves in "MELD pu

242 Incidence of decompensated cirrhosis will increase 168% to 105,430 ca

243 levant outcomes in a cohort of patients with decompensated cirrhosis with acute kidney injury.

244 (n = 100) were divided into cases comprising decompensated cirrhosis with AKI (n = 50) and controls c

245 gulation, and fibrinolysis) in patients with decompensated cirrhosis with and without AKI.

246 , and systemic inflammation in patients with decompensated cirrhosis with and without bacterial infec

247 infusion (CTI) on ascites and sarcopenia in decompensated cirrhosis with portal hypertension.

248 s fluid were collected from 35 patients with decompensated cirrhosis, with or without spontaneous bac

249 after their primary HCV infection developed decompensated cirrhosis within 17 months to 6 years afte

250 is with AKI (n = 50) and controls comprising decompensated cirrhosis without AKI (n = 50).

251 and the number progressing from infection to decompensated cirrhosis would decline by 65%.